ACRX News and Press, AcelRx Pharmaceuticals Inc. From 06/03/22

Buying Penny Stocks on June 3rd? Here’s What You Need to Know If you’re looking to find the best penny stocks to buy right now, there are plenty of options to choose from. And although the stock market is highly volatile in 2022, there is a lot of profit to be had. [...

Buying Penny Stocks on May 26th? Here’s What You Need to Know If you’re looking for penny stocks to buy as May comes to an end, there are plenty of options to choose from. But, understanding exactly what is going on in the stock market and how to take advantage are both cr...

If you’re shopping for a wallet and one comes complete with $100 worth of cash inside, and is priced at $60, would you think there is value to this purchase? A situation similar to this has evolved in many biotech stocks. Their balance sheet cash and cash equivalents exceed their market...

AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Global Investment Conference PR Newswire HAYWARD, Calif. , May 20, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the develop...

AcelRx Pharmaceuticals (NASDAQ:ACRX) on Thursday said the U.S. Food and Drug Administration (FDA) had reduced certain requirements under the drug safety program required for the company's Dsuvia treatment for acute pain. ACRX's Dsuvia is indicated for use in adults only in a medically supervi...

AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA® PR Newswire HAYWARD, Calif. , May 19, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on ...

AcelRx Pharmaceuticals, Inc. (ACRX) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Officer Pamela Palmer - Chief Medical Officer and Co-Founder Conference Call Participants Brandon Folke...

AcelRx Pharmaceuticals press release (NASDAQ:ACRX): Q1 GAAP EPS of -$0.06 in-line. Revenue of $0.44M (-13.7% Y/Y) misses by $0.11M. CEO comment: "Accordingly, we are aligning our cost structure to concentrate on our recently expanded development pipeline, which now includes our nafamostat por...

AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update PR Newswire Realigning cost structure from a focus on commercialization to a focus on development to advance late-stage pipeline; expected to result in annual savings of ...

AcelRx Pharma (NASDAQ:ACRX -5.6%) said on Tuesday that a study found that its drug, sufentanil sublingual tablet 30 mcg, lowered the opioid dose required by patients in the post-anesthesia care unit by more than five-fold compared to standard intravenous opioid administration. The compan...